Product Technology
Andro Diagnostic’s technology is built on the accurate measurement of free zinc concentration in ejaculatory fluid. We are developing a simple reference testing system and reagents that will help physicians confidently and cost-effectively determine the likelihood of prostate cancer. The technology is currently in evaluation in several laboratories in the US under sponsorship of an SBIR Phase 2 Grant. Our pivotal clinical trials for regulatory submission are intended to start in 2010.